Lantheus Holdings Receives FDA Approval For PYLARIFY TruVu Injection

Lantheus Holdings, Inc. (NASDAQ: LNTH) has received FDA approval for its new formulation, PYLARIFY TruVu (piflufolastat F 18) injection. This imaging agent is designed for positron emission tomography (PET) imaging of PSMA positive lesions in men with prostate cancer who are candidates for initial therapy or suspected recurrence. The approval supports Lantheus's commitment to improving patient outcomes in the field of radiopharmaceuticals.